

Hiddo J Lambers Heerspink

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3892522/hiddo-j-lambers-heerspink-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356
papers

20,410
citations

67
h-index

136
g-index

406
ext. papers

28,113
ext. citations

9.1
avg, IF

7.08
L-index

#	Paper	IF	Citations
356	Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure".. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008983	7.6	1
355	Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study.. <i>Kidney International Reports</i> , 2022 , 7, 876-888	4.1	0
354	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.. <i>Kidney International Reports</i> , 2022 , 7, 699-707	4.1	1
353	Kidney and heart failure outcomes associated with SGLT2 inhibitor use.. <i>Nature Reviews Nephrology</i> , 2022 ,	14.9	4
352	Quetelet (Body Mass) Index and Effects of Dapagliflozin in CKD.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	1
351	Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.. <i>American Journal of Nephrology</i> , 2022 , 1-11	4.6	1
350	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.. <i>Kidney International Reports</i> , 2022 , 7, 436-443	4.1	2
349	The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.. <i>Kidney International Reports</i> , 2022 , 7, 1084-1092	4.1	0
348	Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases.. <i>Kidney Medicine</i> , 2022 , 4, 100442	2.8	0
347	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 50	8.7	1
346	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 786767	5.6	0
345	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.. <i>Diabetologia</i> , 2022 , 1	10.3	1
344	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , 2022 ,	16.7	8
343	Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.. <i>Clinical Pharmacokinetics</i> , 2022 , 1	6.2	
342	Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 786706	5.6	2
341	GMP Compliant Synthesis of [¹⁸ F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 16641-16649	8.3	1
340	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3

339	Lipoprotein particle sizes and incident type 2 diabetes: the PREVEND cohort study. <i>Diabetologia</i> , 2021 , 1	10.3	0
338	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
337	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Analysis of the SONAR Randomized Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	1
336	Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. <i>Diabetes Care</i> , 2021 , 44, 440-447	14.6	26
335	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 108077	3.2	0
334	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 743-754	18.1	9
333	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 755-766	18.1	10
332	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1420-1425	6.7	2
331	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021 , 42, 1216-1227	9.5	25
330	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021 , 233, 141-148	4.9	10
329	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1652-1659	6.7	3
328	A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe. <i>Frontiers in Pharmacology</i> , 2021 , 12, 626766	5.6	
327	A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. <i>Cell Metabolism</i> , 2021 , 33, 732-739	24.6	25
326	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1570-1578	4.5	1
325	Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1278-1280	6.9	16
324	Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIABetes and LiFEstyle Cohort Twente (DIALECT). <i>Diabetes Care</i> , 2021 , 44, 1419-1425	14.6	3
323	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. <i>Circulation</i> , 2021 , 143, 1735-1749	16.7	19
322	Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1851-1858	6.7	7

321	FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36,	4.3	1
320	Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1961-1967	6.7	3
319	Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 1049-1052	12.3	1
318	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	7
317	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021 , 30, 456-465	3.5	1
316	Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting. <i>Frontiers in Pharmacology</i> , 2021 , 12, 662642	5.6	1
315	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1956-1960	6.7	2
314	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021 , 44, 1894-1897	14.6	11
313	Precision medicine approaches for diabetic kidney disease: opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 3-9	4.3	3
312	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1447-1455	3.3	2
311	Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. <i>Kidney International Reports</i> , 2021 , 6, 2575-2584	4.1	2
310	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1805-1815	14.6	10
309	Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 382-390	6.7	20
308	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	16.7	69
307	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021 , 143, 438-448	16.7	36
306	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 68-78	12.3	19
305	Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
304	New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. <i>Kidney International</i> , 2021 , 99, 346-349	9.9	10

303	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021 , 174, 385-394	8	25
302	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 94-109	7.4	27
301	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	8.9	23
300	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 22-31	18.1	91
299	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1631-1638	6.1	0
298	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 561-568	6.7	6
297	Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 455-466	6.7	4
296	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021 , 70, 1-16	0.9	18
295	[F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus. <i>Molecular Imaging and Biology</i> , 2021 , 23, 117-126	3.8	2
294	A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 2042018820974191	4.5	1
293	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
292	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 517-525	6.2	0
291	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
290	HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1761-1772	5.6	11
289	SGLT2 inhibitors: expanding their Empire beyond diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 59-61	18.1	1
288	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <i>Lancet, The</i> , 2021 , 398, 262-276	40	35
287	Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 156	8.7	4
286	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021 , 100, 215-224	9.9	35

285	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2352-2361	12.7	13
284	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021 ,	9.5	22
283	Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. <i>Kidney International Reports</i> , 2021 , 6, 2803-2810	4.1	2
282	Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHERE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	1
281	Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2731-2734	12.7	0
280	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA, disease duration and treatment intensity: results from the CANVAS Program. <i>Diabetologia</i> , 2021 , 64, 2402-2414	10.3	2
279	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021 , 9, 807-820	7.9	11
278	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. <i>Diabetologia</i> , 2021 , 64, 2147-2158	10.3	9
277	Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. <i>Antioxidants</i> , 2021 , 10,	7.1	2
276	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2900-2911	12.7	1
275	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. <i>Diabetes Care</i> , 2021 , 44, 2542-2551	14.6	4
274	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2021 ,	9.9	9
273	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 ,	6.9	3
272	Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021661	6	2
271	P1003STUDY DESIGN OF THE ROTATION FOR OPTIMAL TARGETING OF ALBUMINURIA AND TREATMENT EVALUATION (ROTATE-3): A ROTATION STUDY OF DIFFERENT ALBUMINURIA LOWERING DRUGS CLASSES TO STUDY INDIVIDUAL DRUG RESPONSE IN DIABETIC AND NON-DIABETIC CKD. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35,	4.3	2
270	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
269	Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. <i>Translational Research</i> , 2020 , 222, 17-27	11	5
268	High-Density Lipoprotein Particles and Their Relationship to Posttransplantation Diabetes Mellitus in Renal Transplant Recipients. <i>Biomolecules</i> , 2020 , 10,	5.9	2

267	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. <i>Kidney International</i> , 2020 , 98, 769-777	9.9	26
266	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 582-593	18.1	64
265	Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice. <i>Nature Reviews Nephrology</i> , 2020 , 16, 433-434	14.9	1
264	Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empagliflozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 311-321	3.9	9
263	Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, ii38-ii42	4.3	7
262	Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE study). <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1220-1225	6.7	3
261	A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1157-1166	6.7	17
260	Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1152, 122257	3.2	7
259	Prognostic imaging biomarkers for diabetic kidney disease (iBEAT): study protocol. <i>BMC Nephrology</i> , 2020 , 21, 242	2.7	4
258	Reply: Mediators of the Effects of Canagliflozin on Heart Failure: Central Role of the Cardiorenal Axis. <i>JACC: Heart Failure</i> , 2020 , 8, 427	7.9	
257	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020 , 98, 839-848	9.9	65
256	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
255	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 274-282	4.3	105
254	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 301-312	18.1	75
253	Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 916-921	6.7	2
252	Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply. <i>Lancet, The</i> , 2020 , 395, 270	4.0	1
251	Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1556-1566	6.7	9
250	Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. <i>Diabetologia</i> , 2020 , 63, 1128-1140	10.3	22

249	Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 138-147	4.3	27
248	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 57-66	7.9	44
247	Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment 2020 , 211-224		
246	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c. <i>Circulation</i> , 2020 , 141, 407-410	16.7	62
245	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 30-38	6.7	3
244	The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications. <i>Endocrine Reviews</i> , 2020 , 41,	27.2	29
243	Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). <i>European Journal of Heart Failure</i> , 2020 , 22, 713-722	12.3	110
242	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 798-806	6.7	7
241	The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 549-556	6.7	9
240	Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 27-35	18.1	109
239	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 903-914	18.1	34
238	Correction of anemia by dapagliflozin in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020 , 34, 107729	3.2	12
237	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020 , 98, S1-S115	9.9	251
236	Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Analysis from the CREDENCE Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2925-2936	12.7	30
235	Plasma C-Peptide and Risk of Developing Type 2 Diabetes in the General Population. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
234	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020 , 98, 849-859	9.9	19
233	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 1436-1446	14.6	865
232	Effects of Canagliflozin in Patients with Baseline eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1705-1714	6.9	30

231	Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers. <i>Scientific Reports</i> , 2020 , 10, 19743	4.9	3
230	Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. <i>Annals of Internal Medicine</i> , 2020 , 173, 426-435	8	39
229	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 375, 76-91	4.7	3
228	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2446-2456	12.7	5
227	Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. <i>Journal of Hypertension</i> , 2020 , 38, 1811-1819	1.9	7
226	UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma. <i>Bioanalysis</i> , 2020 , 12, 981-990	2.1	0
225	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1700-1711	4.3	52
224	Machine-learning-based early prediction of end-stage renal disease in patients with diabetic kidney disease using clinical trials data. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2479-2486	6.7	10
223	Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCel trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2493-2498	6.7	10
222	Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016976	6	21
221	Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 1570-1576	4.3	9
220	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 94-104	7.4	124
219	Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2192-2203	3.8	3
218	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCel trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 138	8.7	25
217	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 845-854	18.1	335
216	Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. <i>Kidney International</i> , 2019 , 96, 1381-1388	8.9	15
215	When drug treatments bias genetic studies: Mediation and interaction. <i>PLoS ONE</i> , 2019 , 14, e0221209	3.7	0
214	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1735-1745	12.7	68

213	Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 336-337	18.1	9
212	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1237-1250	6.7	114
211	No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2267-2273	6.7	3
210	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 606-617	18.1	304
209	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37
208	Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models. <i>PLoS ONE</i> , 2019 , 14, e0216559	3.7	4
207	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019 , 96, 1030-1036	9.9	15
206	Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. <i>Diabetologia</i> , 2019 , 62, 1154-1166	10.3	144
205	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 429-441	18.1	81
204	Predicting individual treatment response in diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 415-417	18.1	0
203	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 393, 1937-1947	40	209
202	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
201	Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?. <i>Kidney International Reports</i> , 2019 , 4, 212-221	4.1	11
200	Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 633-641	4.3	1
199	The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1921-1929	14.6	21
198	Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2667-2673	6.7	42
197	Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2635-2642	6.7	1
196	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 1756-1769	12.7	31

195	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140
194	Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. <i>Statistics in Medicine</i> , 2019 , 38, 4218-4239	2.3	14
193	The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019 , 10, 2042018819865398	4.5	12
192	Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2422-2428	6.7	23
191	Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors. <i>Atherosclerosis</i> , 2019 , 290, 87-93	3.1	14
190	(Clinical) Trial and Error in Diabetic Nephropathy 2019 , 415-431		
189	Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 2015-2017	4.3	5
188	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2229-2242	12.7	57
187	Change in albuminuria as a surrogate endpoint. <i>Current Opinion in Nephrology and Hypertension</i> , 2019 , 28, 519-526	3.5	5
186	Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1699-1706	4.3	3
185	Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 66-73	6.9	42
184	Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. <i>Journal of Renal Nutrition</i> , 2019 , 29, 276-284	3	5
183	New pharmacological strategies for protecting kidney function in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 397-412	18.1	44
182	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 720-725	6.7	10
181	Future and Novel Compounds in the Treatment of Diabetic Nephropathy 2019 , 515-539		2
180	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 115-127	18.1	114
179	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 128-139	18.1	119
178	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019 , 42, 318-326	14.6	20

177	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 47-56	3.3	9
176	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 296-303	4.3	22
175	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018 , 43, 181-190	3.1	14
174	Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2019-2022	6.7	9
173	Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1988-1993	6.7	111
172	Baseline characteristics and enrichment results from the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1829-1835	6.7	22
171	Epidemiological Applications in -Omics Approaches 2018 , 207-214		
170	Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 2005-2011	4.3	46
169	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018 , 47, 40-47	4.6	101
168	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1369-1376	6.7	49
167	Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1377-1383	6.7	6
166	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , 2018 , 94, 26-39	3.9	160
165	Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 946-948	6.9	6
164	New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. <i>Current Diabetes Reports</i> , 2018 , 18, 27	5.6	36
163	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. <i>European Heart Journal</i> , 2018 , 39, 1535-1542	9.5	118
162	Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 224-227	6.7	12
161	Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2225-2233	12.7	55
160	Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 1947-1954	14.6	25

159	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2899-2904	6.7	7
158	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018 , 71, 91-101	7.4	38
157	Renal trials in diabetes need a platform: time for a global approach?. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 356-358	18.1	8
156	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 925-933	18.1	20
155	Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	14
154	Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 859-869	18.1	122
153	Treating diabetic complications; from large randomized clinical trials to precision medicine. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 3, 3-5	6.7	5
152	New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 3, 14-18	6.7	15
151	Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20 Suppl 3, 19-23	6.7	6
150	Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes. <i>Current Opinion in Nephrology and Hypertension</i> , 2018 , 27, 426-432	3.5	4
149	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2755-2769	12.7	81
148	Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1023-1039	12.7	303
147	Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 391-397	14.6	33
146	Effect of Linagliptin on Arterial F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE). <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1097-1098	15.1	7
145	Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1147-1154	6.7	26
144	Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 545-552	6.7	2
143	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017 , 390, 1888-1917	40	419
142	The albuminuria-lowering GFR response to dapagliflozin is variable and reproducible among individual patients. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1363-1370	6.7	64

141	Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 751-759	6.9	89
140	Variability in response to albuminuria-lowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1197-1204	3.8	14
139	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 749-753	6.7	14
138	Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease. <i>Kidney International Supplements</i> , 2017 , 7, 107-113	6.3	17
137	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1804-1813	6.9	7
136	Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. <i>BMC Nephrology</i> , 2017 , 18, 370	2.7	9
135	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017 , 17, 441-448 ^{3,4}		6
134	Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1595-1600	6.9	2
133	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 718-728	18.1	68
132	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017 , 2, 1066-1075	4.1	55
131	SGLT2 inhibition: a new era in renoprotective medicine?. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 569-571	18.1	6
130	Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The VIRTUE-CKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1296-1305	12.7	28
129	Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 368-375	12.7	220
128	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
127	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1866-1873 ^{4,3}		47
126	Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 70-8	7.4	12
125	Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 249-54	4.3	31
124	Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 1709-14	9.4	4

123	Predictors of HbA1c levels in patients initiating metformin. <i>Current Medical Research and Opinion</i> , 2016 , 32, 2021-2028	2.5	5
122	Novel anti-inflammatory drugs for the treatment of diabetic kidney disease. <i>Diabetologia</i> , 2016 , 59, 1621-33	13.3	14
121	Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1351-1357	3.8	9
120	Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography-Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1440-7	14.6	22
119	Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. <i>Diabetologia</i> , 2016 , 59, 1819-31	10.3	21
118	Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1081-7	4.3	7
117	Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 164-74	27.4	258
116	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 309-17	18.1	31
115	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 758-68	3.9	26
114	Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1471-7	4.3	15
113	MP427BASELINE DATA FROM THE MULTINATIONAL PROSPECTIVE COHORT STUDY FOR VALIDATION OF BIOMARKERS (PROVALID). <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i482-i482	4.3	2
112	Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 169-77	6.7	44
111	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. <i>Journal of Translational Medicine</i> , 2016 , 14, 203	8.5	13
110	Unmet need in diabetic nephropathy: failed drugs or trials?. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 638-640	18.1	33
109	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 3405-3412	12.7	7
108	High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes. <i>Nitric Oxide - Biology and Chemistry</i> , 2016 , 55-56, 18-24	5	23
107	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. <i>Circulation</i> , 2016 , 134, 752-72	16.7	631
106	Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 64-71	6.7	46

105	Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv96-104	4.3	17
104	Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv105-112	4.3	15
103	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 4, iv86-95	4.3	29
102	Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1079-88	6.9	86
101	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 367-81	18.1	63
100	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 602-12	7.4	146
99	A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. <i>PLoS ONE</i> , 2015 , 10, e0120995	3.7	47
98	A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 591-601	7.4	97
97	Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 450-8	7.4	30
96	Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 410-6	6.9	19
95	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 687-96	18.1	173
94	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1568-74	6.9	28
93	Albuminuria 2015 , 663-673		1
92	Renal end points in clinical trials of kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 284-9	3.5	10
91	The blood pressure lowering potential of sulodexide—a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1245-53	3.8	21
90	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015 , 33, 2123-32	1.9	21
89	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 678-86	3.8	32
88	Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 492-7	3.5	3

87	FP272A PANEL OF NOVEL BIOMARKERS REPRESENTING DIFFERENT DISEASE PATHWAYS IMPROVES PREDICTION OF RENAL FUNCTION DECLINE IN TYPE 2 DIABETES. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii158-iii158	4.3	
86	FP348EVIDENCE BASED LEVEL OF THE CKD273 PEPTIDE CLASSIFIER'S UTILITY IN PREDICTING CHRONIC KIDNEY DISEASE PROGRESSION. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, iii184-iii185	4.3	
85	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2289-302	12.7	34
84	Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 259-66	7.4	25
83	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 181-90	18.1	87
82	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 2055-64	12.7	158
81	Diseases of Renal Microcirculation: Diabetic Nephropathy 2015 , 3739-3768		
80	Estimated albumin excretion rate versus urine albumin-creatinine ratio for the assessment of albuminuria: a diagnostic test study from the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 415-21	7.4	27
79	The effect of RAAS blockade on the progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2014 , 10, 77-87	14.9	100
78	Cardiovascular disease in patients with chronic kidney disease. <i>Nephrology</i> , 2014 , 19, 3-10	2.2	11
77	A novel approach for establishing cardiovascular drug efficacy. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 942	64.1	17
76	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1083-93	12.7	168
75	Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 714-22	7.4	54
74	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 299-309	3.9	28
73	Do diabetic kidneys deserve a lifestyle change?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 769-70	18.1	2
72	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2014 , 31, 1138-47	3.5	94
71	Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). <i>American Journal of Kidney Diseases</i> , 2014 , 63, 244-50	7.4	41
70	Improving clinical trial efficiency by biomarker-guided patient selection. <i>Trials</i> , 2014 , 15, 103	2.8	12

69	Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 719-29	18.1	250
68	The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 208-15	6.1	22
67	Sodium excretion and risk of developing coronary heart disease. <i>Circulation</i> , 2014 , 129, 1121-8	16.7	60
66	Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. <i>Diabetes</i> , 2014 , 63, 2845-53	0.9	43
65	Microalbuminuria: target for renoprotective therapy PRO. <i>Kidney International</i> , 2014 , 86, 40-9	9.9	48
64	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 434-41	3.9	18
63	Diseases of Renal Microcirculation: Diabetic Nephropathy 2014 , 1-34		1
62	GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 848-59	7.4	83
61	GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 860-6	7.4	78
60	Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 490-8	6.9	19
59	The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. <i>PLoS ONE</i> , 2014 , 9, e108722	3.7	9
58	Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013 , 37, 212-22	4.6	67
57	Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection. <i>Contributions To Nephrology</i> , 2013 , 179, 7-14	1.6	2
56	Improving the efficacy of RAAS blockade in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2013 , 9, 112-21	14.9	40
55	Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). <i>American Heart Journal</i> , 2013 , 166, 357-364.e2	4.9	77
54	Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. <i>Diabetes Care</i> , 2013 , 36, 1489-94	14.6	26
53	Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. <i>Lancet, The</i> , 2013 , 382, 339-52	40	1105
52	Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. <i>New England Journal of Medicine</i> , 2013 , 369, 2492-503	59.2	662

51	Isolated microalbuminuria indicates a poor medical prognosis. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 1794-801	4.3	14
50	Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 706-15	4.3	12
49	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. <i>Kidney International</i> , 2013 , 83, 517-23	9.9	209
48	PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013 , 11, 162-162	0	
47	Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 853-62	6.7	501
46	Novel drugs and intervention strategies for the treatment of chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 536-50	3.8	32
45	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 2841-50	4.3	18
44	Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 75-83	7.4	139
43	Effect of frozen storage on urinary concentration of kidney damage markers. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 586-9	7.4	16
42	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. <i>Lancet, The</i> , 2012 , 380, 1662-73	4.0	664
41	High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. <i>European Heart Journal</i> , 2012 , 33, 2272-81	9.5	66
40	The geographical distribution of leadership in globalized clinical trials. <i>PLoS ONE</i> , 2012 , 7, e45984	3.7	26
39	Sodium chloride intake: is lower always better?. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1136-9	12.7	19
38	PS12 Contd - 62. Prescribing of aliskiren in practice: findings from the GIANTT diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012 , 10, 142-143	0	
37	Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. <i>Nature Reviews Nephrology</i> , 2012 , 8, 691-9	14.9	24
36	Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. <i>Kidney International</i> , 2012 , 82, 330-7	9.9	159
35	Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 595-603	6.9	25
34	Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 123-30	12.7	116

33	Performance of MDRD study and CKD-EPI equations for long-term follow-up of nondiabetic patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27 Suppl 3, iii89-95	4.3	15
32	Omics-bioinformatics in the context of clinical data. <i>Methods in Molecular Biology</i> , 2011 , 719, 479-97	1.4	13
31	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011 , 79, 1331-40	9.9	468
30	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. <i>Kidney International</i> , 2011 , 80, 282-7	9.9	217
29	Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. <i>American Journal of Kidney Diseases</i> , 2011 , 58, 729-36	7.4	89
28	Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Diabetologia</i> , 2011 , 54, 44-50	10.3	65
27	High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]. <i>Diabetologia</i> , 2011 , 54, 2965-2967	10.3	3
26	Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. <i>Advances in Chronic Kidney Disease</i> , 2011 , 18, 290-9	4.7	9
25	Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. <i>BMJ, The</i> , 2011 , 343, d4366	5.9	189
24	Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. <i>Nephron Clinical Practice</i> , 2011 , 118, c331-8		9
23	Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. <i>Hypertension</i> , 2011 , 58, 2-7	8.5	129
22	initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. <i>Diabetes Care</i> , 2011 , 34, 2078-83	14.6	48
21	Monitoring kidney function and albuminuria in patients with diabetes. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S325-9	14.6	33
20	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. <i>European Heart Journal</i> , 2011 , 32, 1493-9	9.5	99
19	The kidney in type 2 diabetes therapy. <i>Review of Diabetic Studies</i> , 2011 , 8, 392-402	3.6	58
18	Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene-environment interaction in healthy volunteers. <i>Journal of Hypertension</i> , 2010 , 28, 2414-21	1.9	10
17	Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 956-63	6.9	60
16	Comparison of different measures of urinary protein excretion for prediction of renal events. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1355-60	12.7	114

15	Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. <i>European Heart Journal</i> , 2010 , 31, 2888-96	9.5	73
14	Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. <i>American Journal of Nephrology</i> , 2010 , 31, 458-61; discussion 468	4.6	31
13	Composite renal endpoints: was ACCOMPLISH accomplished?. <i>Lancet, The</i> , 2010 , 375, 1140-2	4.0	33
12	Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment 2010 , 105-116		
11	First morning voids are more reliable than spot urine samples to assess microalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 436-43	12.7	172
10	Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. <i>Diabetic Medicine</i> , 2009 , 26, 556-9	3.5	15
9	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009 , 373, 1009-15	4.0	302
8	Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. <i>Journal of Hypertension</i> , 2009 , 27, 2321-31	1.9	21
7	Does the European clinical trials directive really improve clinical trial approval time?. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 546-50	3.8	19
6	Is the randomized controlled drug trial in Europe lagging behind the USA?. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 774-80	3.8	4
5	Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 1946-54	4.3	51
4	Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. <i>American Journal of Epidemiology</i> , 2008 , 168, 897-905	3.8	184
3	Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system. <i>Kidney International</i> , 2008 , 74, 377-83	9.9	10
2	Urinary pH affects albumin concentrations after prolonged frozen storage. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3670	4.3	8
1	Update on microalbuminuria as a biomarker in renal and cardiovascular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 631-6	3.5	56